The White House has withdrawn the nomination of Heidi Overton for head of the Food and Drug Administration (FDA), a White House official told the Guardian. Donald Trump nominated her in August, and her candidacy faced a difficult path to confirmation in the Senate from the outset.
Overton is a doctor and prominent abortion opponent who has spent most of her professional career working directly for Trump or conservative groups aligned with his agenda. Her nomination in August was seen as a move to bring a stable Trump loyalist to the agency, following a turbulent year under the leadership of Trump's first FDA commissioner, Marty Makary.
Republican Senator Bill Cassidy, who chairs the Health, Education, Labor, and Pensions Committee and represents Louisiana, said today that he had remained undecided on her nomination. The committee was due to vote tomorrow. Cassidy called the White House's decision to withdraw the nomination today "strange" and said the White House had abandoned a viable path to confirmation for Dr Overton. According to him, the White House stated that there were not enough votes for her.
Cassidy said he had held productive conversations with members and believed she would have received votes in both the committee and the full Senate. Conversations with her had convinced him, he added, that she would follow the science and resist decisions that endanger Americans' health. He also noted that pro-life senators had sought final assurances from the administration regarding her commitment to life issues, but that the administration preferred to withdraw Dr Overton rather than provide such guarantees. The confirmation of a permanent FDA commissioner would thus fall to Democrats in the Senate, he said.
Overton faced questions from both parties in the Senate regarding her willingness to distance herself from Trump, particularly concerning his unsubstantiated claims about the dangers of childhood vaccines. Cassidy had previously described her support for Trump's plan to break up combined vaccines, including the measles, mumps and rubella vaccine, as "nearly disqualifying". At a September hearing, he questioned her scientific independence and willingness to stand up to Trump and Health Secretary Robert F. Kennedy Jr., a long-time critic of vaccines.
For confirmation, Overton would have needed the votes of all 12 Republicans on the Health, Education, Labor, and Pensions Committee, while Democrats hold 11 seats. Without committee support, she had little chance of a vote in the full Senate. Republicans are rushing to confirm all of Trump's current nominations before handing control of the Senate to Democrats in January.
A prominent reproductive rights group welcomed the White House's decision. Mini Timmaraju, president and chief executive of Reproductive Freedom for All, formerly NARAL Pro-Choice America, stated that Heidi Overton represented a serious threat to the future of access to medication abortion. She said voters across the country had rejected that anti-abortion agenda and that members of the organisation had maintained pressure to thwart her confirmation. If Republicans attempt to push through a second candidate who threatens our healthcare, we are ready to continue the fight, she said.
As FDA head, Overton would oversee the agency that regulates medication abortion. In a 2023 political review for the conservative America First Policy Institute, she wrote that Congress should strictly regulate the abortion pill mifepristone "to protect women and children". She criticised federal policies that allow abortion pills to be sent by post, and wrote that abortion is "corrosive to children, women and society as a whole".













